Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...
In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...
Zacks Investment Research on MSN
GSK gets EU approval for expanded use of Nucala in COPD
GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...
GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive pulmonary disease (COPD). Read more here.
Please provide your email address to receive an email when new articles are posted on . Smoking abstinence during week 9 to week 12 among adults with COPD was 19.1% with 12-cytisinicline vs. 4.3% with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results